Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder

Joep Schoemaker, Dieter Naber, Peter Vrijland, John Panagides, Robin Emsley

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Introduction: We conducted a double-blind 1-year trial of asenapine in patients with schizophrenia or schizoaffective disorder. Methods: Patients were randomized to asenapine (5 or 10 mg BID; n=913) or olanzapine (10–20 mg QD; n=312), and monitored regularly. Results: Trial completion rates were 38% with asenapine and 57% with olanzapine; main reasons for discontinuation were withdrawal of consent (22%, 16%) and insufficient response (25%, 14%); fewer discontinuations were due to adverse events (6%, 7%). Mean weight gain was 0.9 kg with asenapine, and 4.2 kg with olanzapine. Extrapyramidal symptoms reported as adverse events were more common with asenapine. Mean reductions in PANSS total score with asenapine and olanzapine were –21.0 and –27.5 (P<0.0001); the exclusion of patients who had previous poor experience with olanzapine may have biased the results in favor of olanzapine. Scores on the Subjective Wellbeing on Neuroleptics scale and functionality measures were similar between groups. Conclusion: Asenapine was well tolerated over one year of treatment, causing less weight gain than olanzapine but more frequent extrapyramidal symptoms. PANSS total score improved with both agents; the improvement was greater with olanzapine than with asenapine using last observations carried forward but not in an observed-case analysis.
Original languageEnglish
Pages (from-to)138-146
JournalPharmacopsychiatry
Volume43
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Weight Gain
Asenapine

Cite this

Schoemaker, J., Naber, D., Vrijland, P., Panagides, J., & Emsley, R. (2010). Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. Pharmacopsychiatry, 43, 138-146.
Schoemaker, Joep ; Naber, Dieter ; Vrijland, Peter ; Panagides, John ; Emsley, Robin. / Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. In: Pharmacopsychiatry. 2010 ; Vol. 43. pp. 138-146.
@article{712a90acca0d4bc68d2c16d195d0a1c6,
title = "Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder",
abstract = "Introduction: We conducted a double-blind 1-year trial of asenapine in patients with schizophrenia or schizoaffective disorder. Methods: Patients were randomized to asenapine (5 or 10 mg BID; n=913) or olanzapine (10–20 mg QD; n=312), and monitored regularly. Results: Trial completion rates were 38{\%} with asenapine and 57{\%} with olanzapine; main reasons for discontinuation were withdrawal of consent (22{\%}, 16{\%}) and insufficient response (25{\%}, 14{\%}); fewer discontinuations were due to adverse events (6{\%}, 7{\%}). Mean weight gain was 0.9 kg with asenapine, and 4.2 kg with olanzapine. Extrapyramidal symptoms reported as adverse events were more common with asenapine. Mean reductions in PANSS total score with asenapine and olanzapine were –21.0 and –27.5 (P<0.0001); the exclusion of patients who had previous poor experience with olanzapine may have biased the results in favor of olanzapine. Scores on the Subjective Wellbeing on Neuroleptics scale and functionality measures were similar between groups. Conclusion: Asenapine was well tolerated over one year of treatment, causing less weight gain than olanzapine but more frequent extrapyramidal symptoms. PANSS total score improved with both agents; the improvement was greater with olanzapine than with asenapine using last observations carried forward but not in an observed-case analysis.",
author = "Joep Schoemaker and Dieter Naber and Peter Vrijland and John Panagides and Robin Emsley",
note = "An Erratum to this publication appeared in: Pharmacopsychiatry, 2011, 44, 343. DOI: http://dx.doi.org/10.1055/s-0030-1248313",
year = "2010",
language = "English",
volume = "43",
pages = "138--146",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",

}

Schoemaker, J, Naber, D, Vrijland, P, Panagides, J & Emsley, R 2010, 'Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder', Pharmacopsychiatry, vol. 43, pp. 138-146.

Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. / Schoemaker, Joep; Naber, Dieter; Vrijland, Peter; Panagides, John; Emsley, Robin.

In: Pharmacopsychiatry, Vol. 43, 2010, p. 138-146.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Long-Term Assessment of Asenapine vs .. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder

AU - Schoemaker, Joep

AU - Naber, Dieter

AU - Vrijland, Peter

AU - Panagides, John

AU - Emsley, Robin

N1 - An Erratum to this publication appeared in: Pharmacopsychiatry, 2011, 44, 343. DOI: http://dx.doi.org/10.1055/s-0030-1248313

PY - 2010

Y1 - 2010

N2 - Introduction: We conducted a double-blind 1-year trial of asenapine in patients with schizophrenia or schizoaffective disorder. Methods: Patients were randomized to asenapine (5 or 10 mg BID; n=913) or olanzapine (10–20 mg QD; n=312), and monitored regularly. Results: Trial completion rates were 38% with asenapine and 57% with olanzapine; main reasons for discontinuation were withdrawal of consent (22%, 16%) and insufficient response (25%, 14%); fewer discontinuations were due to adverse events (6%, 7%). Mean weight gain was 0.9 kg with asenapine, and 4.2 kg with olanzapine. Extrapyramidal symptoms reported as adverse events were more common with asenapine. Mean reductions in PANSS total score with asenapine and olanzapine were –21.0 and –27.5 (P<0.0001); the exclusion of patients who had previous poor experience with olanzapine may have biased the results in favor of olanzapine. Scores on the Subjective Wellbeing on Neuroleptics scale and functionality measures were similar between groups. Conclusion: Asenapine was well tolerated over one year of treatment, causing less weight gain than olanzapine but more frequent extrapyramidal symptoms. PANSS total score improved with both agents; the improvement was greater with olanzapine than with asenapine using last observations carried forward but not in an observed-case analysis.

AB - Introduction: We conducted a double-blind 1-year trial of asenapine in patients with schizophrenia or schizoaffective disorder. Methods: Patients were randomized to asenapine (5 or 10 mg BID; n=913) or olanzapine (10–20 mg QD; n=312), and monitored regularly. Results: Trial completion rates were 38% with asenapine and 57% with olanzapine; main reasons for discontinuation were withdrawal of consent (22%, 16%) and insufficient response (25%, 14%); fewer discontinuations were due to adverse events (6%, 7%). Mean weight gain was 0.9 kg with asenapine, and 4.2 kg with olanzapine. Extrapyramidal symptoms reported as adverse events were more common with asenapine. Mean reductions in PANSS total score with asenapine and olanzapine were –21.0 and –27.5 (P<0.0001); the exclusion of patients who had previous poor experience with olanzapine may have biased the results in favor of olanzapine. Scores on the Subjective Wellbeing on Neuroleptics scale and functionality measures were similar between groups. Conclusion: Asenapine was well tolerated over one year of treatment, causing less weight gain than olanzapine but more frequent extrapyramidal symptoms. PANSS total score improved with both agents; the improvement was greater with olanzapine than with asenapine using last observations carried forward but not in an observed-case analysis.

M3 - Article

VL - 43

SP - 138

EP - 146

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

ER -